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Translational Relevance 
 
More than half of patients receive radiotherapy as part of their cancer treatment. 
Significant technical advances have been made in radiotherapy delivery, but little 
progress has been made in combining new cancer drugs with radiotherapy to improve 
the efficacy of combination treatment. In view of this lack of progress, the FDA-
AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations 
Workshop was held in February 2018 to bring together stakeholders and opinion 
leaders from academia, clinical radiation oncology, industry, patient advocacy groups 
and the FDA in order to discuss challenges to introducing new drug-radiotherapy 
combinations to the clinic. This article summarises the themes and action points that 
were discussed to increase the number of novel drugs being successfully registered in 
combination with radiotherapy to improve clinical outcomes for patients with cancer.  
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Abstract  
 
Radiotherapy is a fundamental component of treatment for the majority of patients 
with cancer. In recent decades, technological advances have enabled patients to 
receive more targeted doses of radiation to the tumour, with sparing of adjacent 
normal tissues. There had been hope that the era of precision medicine would enhance 
the combination of radiotherapy with targeted anticancer drugs, however this 
ambition remains to be realised. In view of this lack of progress, the FDA-AACR-
ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop was 
held in February 2018 to bring together stakeholders and opinion leaders from 
academia, clinical radiation oncology, industry, patient advocacy groups and the FDA 
in order to discuss challenges to introducing new drug-radiotherapy combinations to 
the clinic. This Perspectives in Regulatory Science and Policy article summarises the 
themes and action points that were discussed.  Intelligent trial design is required to 
increase the number of studies which efficiently meet their primary outcomes; 
endpoints to be considered include local control, organ preservation and patient-
reported outcomes. Novel approaches including immune-oncology or DNA repair 
inhibitor agents combined with radiotherapy should be prioritised. In this article, we 
focus on how the regulatory challenges associated with defining a new drug-
radiotherapy combination can be overcome in order to improve clinical outcomes for 
patients with cancer.  
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Introduction 
 
The FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations 
Workshop took place on February 22-23 2018 in Bethesda, Maryland in response to a 
consensus paper published on this topic led by the UK National Cancer Research 
Institute (NCRI) (1). The Workshop’s principal aim was to bring together over 400 
stakeholders and key opinion leaders from academia, clinical radiation oncology, 
industry, patient advocacy groups and the FDA to provide a forum to discuss real and 
perceived challenges to introducing new drug-radiotherapy combinations to the clinic. 
The primary outputs of this Workshop are summarized here (Textbox 1).  In this 
article, we discuss the current landscape of drug-radiotherapy combinations, 
challenges associated with the development and approval of drug-radiotherapy 
combinations, and strategies that may be adopted by stakeholders to help overcome 
them.          
 
 
The unrealised potential of drug-radiotherapy combinations 
 
Radiotherapy is a key component in the management of 40% of cancer patients cured 
of their disease (2). Moreover it provides a highly effective treatment strategy for the 
palliation of symptoms in individuals suffering with advanced disease. There have 
been major advances in radiation technology over recent years.  Radiotherapy is a 
cost-effective treatment modality (3).    
 
In the radical treatment of cancer when the treatment intent is cure, radiotherapy is 
often combined with conventional cytotoxic drugs such as cisplatin or 5-fluorouracil. 
This radiosensitization approach is supported by robust Level 1 evidence (4). Within 
recent decades, the advent of precision medicine has shifted the focus of cancer drug 
discovery towards targeting specific proteins and pathways for therapeutic gain. This, 
along with advances in immuno-oncology (IO), has been associated with dramatic 
improvements in clinical outcomes (5-7). These observations have led researchers to 
hypothesize that similar benefits may be realised through combining novel targeted 
drugs with radiation.  
 
The scientific rationale for combining radiotherapy with novel targeted agents has 
been appraised in previous reviews (1,4). The aim of any treatment combination is to 
improve the therapeutic ratio such that the anti-cancer effect is enhanced over and 
above any corresponding increase in normal tissue toxicity.  
 
The FDA granted approval to a combination of radiotherapy with a targeted agent in 
March 2006. However in the 12 years that have followed, no new drug-radiotherapy 
combinations have been approved (8). The combinatory drug approved at that time 
was cetuximab – an anti-epidermal growth factor receptor (EGFR) monoclonal 
antibody – for use in head and neck cancers. It had been widely perceived that, as 
more novel targeted agents entered the clinic, the number of clinically effective drug-
radiotherapy combinations would also significantly increase.  
 
While no new drug-radiotherapy combinations have passed regulatory approval 
during this period, the FDA has approved more than 130 novel drug indications in 
oncology. Moreover a Pubmed database search for entries from 2006 onwards using 
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the keyword ‘radiosensitization’ identifies 1713 articles published, suggesting that 
pre-clinical and clinical research in this area remains highly active. So what is driving 
this stark disparity? It was with this question in mind that the FDA-AACR-ASTRO 
Workshop was developed.  
 
What Guidance is Required to Make Progress? 
 
A number of factors were identified that implied that the pathway to approval of a 
novel drug-radiotherapy combination is hindered from Day Zero. To date, the FDA 
has not published a regulatory guidance document specifically detailing the approval 
pathway for a drug-radiotherapy combination. Pharmaceutical industry 
representatives cited the lack of regulatory guidance as a significant hurdle. Without 
regulatory guidelines to support drug development, strategic decisions on investment 
into drug-radiotherapy combinations cannot be de-risked against specific criteria 
pertaining to approval. This may result in combination strategies being de-prioritised. 
However, there is no published evidence that the publication of a specific regulatory 
guidance document increases industry-led drug development within that area. Some 
of the existing regulatory guidance on drug-drug combinations may in fact be applied 
to drug-radiotherapy combinations (see below) (9).  
 
There is evidence of a significant lag time in testing drugs in combination with 
radiotherapy during the clinical development of a novel agent (10,11). One study 
demonstrated the median interval between the opening of phase 1 trials without 
radiotherapy, and those with, was 6 years. Further, phase 1 trials with radiotherapy 
were typically published after 9 years of the drug patent had lapsed (11). With drug 
patents limited to 20 years, a lag of this magnitude would significantly diminish the 
potential profitability of a drug-radiotherapy combination. In light of this, there are 
few incentives for pharmaceutical companies to take promising phase 1 data through 
to a costly phase 3 registration study with radiation. This is particularly true given the 
high attrition rates seen from phase 1 to phase 3. 
 
Pharmaceutical companies are further discouraged from investigating drug-
radiotherapy combinations due to misconceptions and uncertainty around the pre-
clinical data required for regulatory approval, particularly regarding safety. Moreover, 
generating appropriate pre-clinical data in the context of radiation requires special 
assays and know-how to which pharmaceutical companies may not have access. At 
the Workshop, FDA representatives provided detailed clarification on this matter and 
a summary is provided in Textbox 2.  
 
Regulators highlighted the challenge of providing a comprehensive guidance 
document due to the many possible development scenarios for drug-radiotherapy 
approaches. As with many development programs, each case is unique and the most 
detailed advice to sponsors can be offered when the FDA performs clinical trial 
reviews for investigational new drug applications. It was suggested that industry 
representatives arrange formal meetings with the FDA at an early stage to help define 
a clear line of sight to registration for each individual drug-radiotherapy combination 
(12). For broader advice, much of the guidance relating to drug-drug combinations 
may be applicable to combinations with radiation (9).  
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Toxicity data for new treatment combinations may not be required, depending on the 
extent of toxicity data available for each individual agent (13). A strong rationale for 
combining the drug with radiation should be presented with consideration given to 
potential organs at risk of toxicity.  If this is based on clear and robust science further 
pre-clinical experiments to support the hypothesis are not always necessary. Again, 
case-by-case discussions with regulators should be sought.  
 
In the case of investigational compounds at early stages of development (i.e. human 
toxicity data remains uncharacterised), pre-clinical data with a particular focus on 
safety, are necessary. A pharmacology study supporting the rationale for the 
combination should be provided. Such a study should demonstrate increased activity 
in the absence of a substantial increase in toxicity on the basis of limited safety 
endpoints, such as mortality, clinical signs and body weight. 
 
The role of pre-clinical data within the regulatory approval process represents a 
relatively ‘easy-win’ for industry. For drugs already approved in most circumstances, 
there may be no need to generate further pre-clinical data. In drugs at earlier stages of 
development, there are significant incentives in performing the pre-clinical 
experiments outlined in Textbox 2 as the drug may subsequently be approved in 
combination with radiation for a longer duration during the compound’s patent. These 
experiments may be performed in collaboration with partners in academia. Indeed, 
throughout the Workshop there were calls to improve communication between 
industry and academia/radiation oncology.  
 
An increasing number of assays and model systems have been studied that examine 
radiation-related toxicity (14). Murine models can be utilised to study the effects of 
thoracic radiation with and without a novel targeted agent. Early access to these 
model systems during the drug discovery process would enable the prioritisation of 
agents as clinical radiosensitizers (15). However, the development of model systems 
predicting radiation-related toxicity remains at an early stage and consequently data 
generated from these models should not be over-interpreted.  
 
Finally, discussions between radiation oncologists and industry will ensure industry-
led studies are designed to collect data on long-term toxicity. This area is often 
neglected in drug-only studies but is critical to radiotherapy as it is late toxicities that 
are dose-limiting.   
 
 
How to Improve the Design of Future Clinical Trials? 
 
A large number of clinical trials investigating novel drug-radiotherapy combinations 
have been negative studies. Historically studies have not enriched for, or sub-stratified 
patients based on, genotypic or phenotypic information to increase the likelihood of a 
positive outcome. For instance, there are compelling non-clinical data to suggest that 
hypoxia-modifying agents may improve radiotherapy outcomes (16). However. 
clinical trial data have been underwhelming, and a potential reason for this is that 
patients were not selected on the basis of their tumor’s hypoxic status (17).  
 
Further, the outcome data from radiotherapy-based clinical studies may be 
confounded by variability in radiotherapy technique across participating centers (18). 
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Data from the RTOG 0617 study investigating radiotherapy dose escalation in the 
treatment of non-small cell lung cancer demonstrated improved overall survival (OS) 
in patients treated at institutions with higher clinical trial accrual volumes (19).  
 
Apart from radiotherapy technique, dose-fractionation and drug scheduling are also 
likely to be of significance, particularly in the context of IO agents in combination 
with radiotherapy. For instance, pre-clinical data have shown that PD-L1 blockade 
can overcome resistance to fractionated low-dose radiotherapy but not high-dose 
radiotherapy (20). This observation is by no means generalizable and our 
understanding of the interaction of radiation with the host immune system remains 
only partly understood (21).  
 
A number of potential solutions may help to improve the design of clinical drug-
radiotherapy trials. Biomarker-driven studies should allow more evidence-based 
patient selection ensuring that the efficacy of a novel agent is more accurately 
evaluated. To bolster the development of biomarkers, window-of-opportunity studies 
in the neoadjuvant setting may be of more value as they allow access to tumor tissue 
to assess for pharmacodynamic (PD) studies. Furthermore, since phase 1 toxicity 
studies are often limited to specific anatomic sites and may not be generalizable to 
other cancers with a different spectrum of normal tissue toxicities, umbrella studies 
(one cancer – multiple mutations - multiple drugs) and basket studies (multiple 
cancers – one mutation – one drug) run using adaptive trial designs should be 
considered to allow more efficient use of resources and enable multiple hypotheses to 
be tested within one clinical trial.  
 
The role of radiotherapy quality assurance (RTQA) within all clinical studies cannot 
be overstated and efforts to harmonize international RTQA standards are essential. 
Within the US, the Imaging and Radiation Oncology Core (IROC) run out of the MD 
Anderson Cancer Center has developed many important resources enabling robust 
RTQA. Within the UK, this role is taken by the RTTQA group (22). However the 
challenges associated with RTQA must also be acknowledged and addressed. 
Providing real-time QA such that plans are appraised prior to the patient starting 
treatment is significantly resource-intensive. Investments in human and computing 
resources will partly address this problem however more imaginative solutions such 
as artificial intelligence-based QA strategies may also be of value.      
 
Uncertainties around RT scheduling and fractionation in combination with IO and 
other novel agents must be informed by preclinical evidence. However these efforts 
should not significantly delay clinical studies which should be designed so that tissue 
samples can be used to back-translate into the laboratory to better understand the 
biology behind the responses seen in vivo. 
 
Classically recognized regulatory endpoints for clinical trials of systemic treatment 
such as disease-free survival (DFS) and OS may be impractical for some clinical trials 
of new drug-radiotherapy combinations in the context of a local treatment used with 
curative intent. OS endpoints may take many years to be reached in patients with 
good prognosis diseases. Established endpoints such as DFS or OS can still be 
evaluated as secondary endpoints during longer-term follow-up to confirm clinical 
benefit in a study that meets an earlier, primary endpoint.  
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Common early endpoints such as local control can provide evidence of anti-tumor 
activity and could be supported by clinically relevant endpoints such as organ 
preservation rates and assessment of symptoms and function using clinical outcome 
assessments (Table 1 and Textbox 3). Regulatory approval could potentially be 
granted based on earlier endpoints. There is a clear need to develop early and 
intermediate endpoints of the efficacy, and toxicity, of the new combination. 
Appropriate early endpoints are likely to be sub-site specific and therefore a 
consensus should be reached in partnership with the FDA potentially through organ-
specific workshops. There are valid concerns that endpoints such as organ-
preservation may be influenced by bias, thus trial protocols should seek to define 
prospective criteria for surgical intervention.   
 
 
 
Dialogue between Key Stakeholders 
 
At the Workshop, it was acknowledged that the lack of clinical trial activity 
investigating novel drug-radiotherapy combinations has contributed to the lack of 
successful regulatory approvals. The incentives underlying academic interest in 
combining radiation with novel drugs is likely to differ significantly from those 
within industry. Within the US, perceived tensions between medical and radiation 
oncologists may also exist due to historically low levels of research collaboration.  
Moreover, the FDA as a regulatory body weighs the balance between safety and 
efficacy from a different perspective for a patient with early-stage disease compared 
to a patient with terminal cancer with no treatment options available. Consequently, 
dialogue and collaboration between the stakeholders involved in the clinical 
development of drug-radiotherapy combinations is critical to enable a better 
understanding and alignment of interests.  
 
Initiatives should be prioritized to improve collaboration, and this includes 
engagement with patient advocacy groups (Textbox 4). An example of this is the 
RaDCom program in the UK (23) which is a formal collaboration across multiple 
disciplines with the primary aim of improving the development of drug-radiotherapy 
combinations. Multi-center trials will be necessary to investigate many of the 
potential combinations, and one barrier that was identified is the perception that 
academic clinical investigators are not sufficiently rewarded for their participation in 
these trials by research funding bodies such as the National Cancer Institute. Finally 
the academic community should reach a consensus as to which areas to prioritise, for 
instance IO with radiotherapy, to generate a sufficient critical mass of personnel and 
resources to perform large-scale practice-changing research.  
 
 
Conclusions 
 
We have witnessed the recent approval of many systemic therapies with varied 
mechanisms of action leading to an unprecedented opportunity to investigate new 
drug-radiotherapy combinations. Perceived challenges associated with generating pre-
clinical data and establishing trial endpoints for registration should be readily 
tractable. Insufficient novel drug-radiotherapy combinations have reached the clinic, 
and the attendees of this Workshop identified several opportunities to foster 
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development in this important cancer therapeutic space. Workshop participants felt 
energized to take forward the solutions proposed in this summary article to transform 
the landscape of translational radiation biology and significantly improve clinical 
outcomes for cancer patients.       
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Table 1:  Summary of clinical trial endpoints to be considered in testing new drug-
radiotherapy combinations 
 
Endpoint Advantages Disadvantages 
Overall 
survival 
 
- Universally accepted measure of 
direct benefit 
- Easily and precisely measurable 
- Blinding not needed 
- Trials in radical setting will generally 
be of a long duration 
- May require larger trials 
- May be affected by crossover and 
subsequent therapies 
- Includes non-cancer deaths 
Symptom 
endpoints/ 
patient 
reported 
outcomes 
- Patient perspective of direct clinical 
benefit 
- Data acquisition ideal for 
incorporation into digital health 
technologies 
 
- Blinding often difficult 
- Data frequently missing or incomplete 
- Clinical significance of small changes 
unknown 
- Lack of validated instruments 
- Bias from multiple-testing may occur 
Organ-
preservation 
- Important endpoint for patients 
- Ideal in head and neck cancer 
(tracheostomy-free) and bladder 
cancer (bladder-preservation) trials 
- Easily measurable 
- Without blinding and clear protocols, 
surgical timing may be subject to bias 
- Limited to certain disease sites 
Loco-regional 
control 
- Applicable to most cancers treated 
with RT 
- Smaller sample size and follow-up 
duration compared to survival studies 
- Unaffected by crossover and 
subsequent therapies 
- Generally based on objective 
quantitative assessment 
- May be more reflective of RT effect 
than disease-free survival 
- Also influenced by surgery and/or 
chemotherapy therefore may not be a 
direct measure of RT effect 
- Definitions may vary based on trials 
- May not be of clinical significance in 
all settings 
- Not precisely measured and may be 
subject to assessment bias 
- Radiological or other assessments 
must be frequent and balanced across 
treatment arms  
Disease-free 
survival 
- In some scenarios, may correlate 
better with overall survival than local 
control 
- May capture abscopal effects of IO-
RT better than local control  
- As per loco-regional control above 
Complete or 
objective 
response 
rates 
- Suitable for neoadjuvant studies 
- Assessed earlier and in smaller 
studies compared to survival studies 
- Not a direct measure of benefit in all 
cases 
- Only a subset of patients who benefit 
Progression-
free survival 
(includes all 
deaths) or 
time to 
progression 
(deaths before 
progression 
censored)* 
- May be suitable in IO-RT studies 
within metastatic setting 
- Assessed earlier and in smaller 
studies compared to survival studies 
- Stable disease included 
- Unaffected by crossover and 
subsequent therapies 
 
- Not valid surrogate for survival in all 
settings 
- Not precisely measured and may be 
subject to assessment bias 
- Frequent radiological or other 
assessments required 
- Less relevant for drug-RT trials  
 
Abbreviations used:  IO – immuno-oncology, RT - radiotherapy 
 
*Landmark analyses associated with these endpoints may be particularly suitable for 
IO-RT trials. In landmark analyses, a fixed-time after the initiation of therapy is 
selected and only patients alive at that time are included in the analysis, separated into 
2 response categories according to whether they have responded up to that time. 
